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Effect of cannabis smoking on lung function and respiratory
symptoms: a structured literature review
Luis IG Ribeiro1 and Philip W Ind2
As cannabis use increases, physicians need to be familiar with the effects of both cannabis and tobacco on the lungs. However,
there have been very few long-term studies of cannabis smoking, mostly due to legality issues and the confounding effects of
tobacco. It was previously thought that cannabis and tobacco had similar long-term effects as both cause chronic bronchitis.
However, recent large studies have shown that, instead of reducing forced expiratory volume in 1 s and forced vital capacity (FVC),
marijuana smoking is associated with increased FVC. The cause of this is unclear, but acute bronchodilator and anti-inﬂammatory
effects of cannabis may be relevant. Bullous lung disease, barotrauma and cannabis smoking have been recognised in case reports
and small series. More work is needed to address the effects of cannabis on lung function, imaging and histological changes.
npj Primary Care Respiratory Medicine (2016) 26, 16071; doi:10.1038/npjpcrm.2016.71; published online 20 October 2016
INTRODUCTION
As most people are aware, marijuana is the most widely used illicit
drug in the world.1 Cannabis is the second most smoked
substance, after tobacco. In the past few years, recreational use
of cannabis (‘weed’, ‘dope’, ‘grass’, ‘spliff’, ‘toke’, ‘hash’, ‘hemp’,
‘bud’, ‘ganja’ and many others) has had increasing media attention
and, with legislation in various countries being relaxed, it appears
likely that there will be an increase in exposure generally.
However, we still know very little about the long-term effects of
smoking cannabis on the respiratory system and on health in
general.
Cannabis comes from a ﬂowering plant, native to central Asia
and the Indian sub-continent. The genus includes three
different species—Cannabis sativa, Cannabis indica and Cannabis
ruderalis. They produce two major active compounds, delta-9-
tetrahydrocannabinol (d-9-THC) and cannabidiol (CBD); however,
they contain 60 cannabinoids and over 400 compounds in total.2
THC is the psychoactive compound, but it is modulated by CBD.
The C. sativa-dominant strains have higher THC content, whereas
the C. indica-dominant strains have higher CBD content.2 The
C. ruderalis-dominant strains contain even lower THC concentra-
tions than the C. indica-dominant strains.3 There is also ‘skunk-like’
cannabis, named for its smell, containing very high THC
concentrations.4
Experimentally, the acute bronchodilator effect5,6 and analgesic
properties7–9 of inhaled cannabis are well described. Acute
bronchodilatation is due to THC.4 However, as cannabinoids can
have partial agonist, or even antagonist, effects, little is known
about differences in airway effects from different strains of
cannabis containing varying concentrations of cannabinols.
Evidence that chronic cannabis users have an increased
incidence of respiratory symptoms such as chronic cough, sputum
production, dyspnoea, hoarse voice and chest tightness has been
reviewed recently.6,10 As marijuana smoke contains many of the
same compounds as, and shares similar properties with, cigarette
smoke, respiratory symptoms would be expected.11,12
Methodological difﬁculties
There are obvious inherent difﬁculties in studying the long-term
use of illicit substances. Examining dose–response is confounded
by the problem of quantifying cannabis use—the measurement of
‘joint-years’ has inherent difﬁculties. One joint-year is deﬁned as
365 joints smoked. However, because of the wide variety and
strengths of marijuana in a joint,13,14 as well as the varying
amounts that individuals put into a joint, this measure differs
markedly between individuals. Reproducibility of joints in the
same individual is not well deﬁned. Furthermore, most studies use
self-reported joint-years to quantify use; this may be inaccurate
owing to the legality of cannabis use, recall bias and alteration of
behaviour by its observation.
Another major consideration is the variety of ways that
cannabis can be smoked, which alter the characteristics of
the smoke inhaled. Using a water bong, e.g., decreased the
concentration of inhaled carcinogenic compounds.11,15 Recent
evidence has suggested that using a vapouriser to smoke
cannabis may reduce pulmonary complications.16 Otherwise,
there have been no peer-reviewed studies examining the effects
of differing methods of smoking cannabis on lung health .
Cannabis and tobacco tend to be smoked differently. Typically,
cannabis is smoked without a ﬁlter, to a shorter butt length, and
the smoke is at a higher temperature. Furthermore, cannabis
smokers inhale more deeply, hold their breath for longer and
perform a Valsalva manoeuvre at maximal breath-hold.17–19
Some smokers make joints with marijuana leaves alone,20
whereas others usually smoke ‘spliffs’ containing both cannabis
and tobacco leaves.21 This varies from one country to another.
Cannabis users are also more likely to concurrently smoke
tobacco, separately, making it difﬁcult to disentangle the effects
of cannabis itself on the lungs.
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Table 1. Summary of studies on the association between chronic cannabis use and lung function
Author (year) Subjects
(n)
Tobacco
control
Results
Cruickshank23 60 No No signiﬁcant differences found between cannabis smokers and control with respect to FEV1 and FVC.
Tashkin
et al.28
74 Yes No differences in spirometry results compared with those in matched and unmatched controls. A signiﬁcant
increase was noted in Raw and decrease in sGaw compared with those in both controls. Although not
signﬁcant, FVC was raised compared with that in both controls.
Hernandez
et al.24
23 No Spirometry results of marijuana smokers were not signiﬁcantly different from those of controls. There was also
no signiﬁcant difference in bronchial reactivity to histamine compared with controls.
Tilles et al.31 68 Yes Cannabis smoking with or without tobacco smoking was associated with a reduction in TLco
(74% predicted± 20%, Po0.05). In marijuana and marijuana plus tobacco smokers, both FEV1 and FVC were
signiﬁcantly increased compared with that in non-smokers.
Bloom
et al.22,a
990 Yes There was a signiﬁcant increase in respiratory symptoms of phlegm and wheeze, but not cough or shortness of
breath, in non-tobacco cigarette smokers whether or not they had ever smoked tobacco cigarettes. There was a
signiﬁcant decrease in FEV1/FVC compared with that in controls. There was no signiﬁcant change in FEV1 in any
non-tobacco-smoking category.
Tashkin
et al.29
446 Yes Smokers of marijuana and/or tobacco had signiﬁcantly increased rates of chronic cough, wheeze and sputum
production. There was an increase in Raw and decrease in sGaw in male marijuana smokers but not in tobacco
smokers. FEV1 and FVC of marijuana smokers were not signiﬁcantly different from those of controls.
Sherrill et al.34 856 Yes Non-tobacco smoking was associated with chronic cough (OR= 1.73), chronic phlegm (OR= 1.53) and wheeze
(OR= 2.01). There was a signiﬁcant reduction in FEV1 and FEV1/FVC ratios with previous
non-tobacco smoking but not with current smoking.
Sherman
et al.27
63 Yes Macrophage oxidant release, small airway integrity and alveolar gas exchange were similar in both
non-smokers and marijuana smokers. There was no signiﬁcant difference in lung function measurements
between marijuana-only smokers and non-smokers. Marijuana and tobacco concurrent smokers showed a
decrease in FEV1/FVC and TLco.
Tashkin
et al.30
542 Yes No signiﬁcant difference in AHR to metacholine was found in non-smokers and marijuana smokers without
tobacco. Logistic regression showed a signiﬁcant response to metacholine with marijuana smoking, however.
No dose–response relationship was found between AHR and lifetime marijuana use.
Tashkin
et al.36
394 Yes Although tobacco smoking showed an FEV1 decline in men, marijuana smoking was not associated with FEV1
decline in either gender.
Taylor
et al.38,a
1037 Yes After controlling for tobacco, cannabis users had an increase in wheezing, exercise-related shortness of breath,
nocturnal wakening with chest tightness and morning sputum production (Po0.05). Cannabis users had
decreased FEV1/FVC compared with non-smokers. There was no signiﬁcant increase in AHR in tobacco or
cannabis users.
Taylor
et al.37,a
1037 Yes After stratifying by use of cannabis, at each age increasing cannabis use was associated with a decline in FEV1/
FVC. After adjustments for other co-variates, cannabis as a predictor was only marginally signiﬁcant (Po0.09).
Moore et al.26 6728 Yes Marijuana use was signiﬁcantly associated with chronic bronchitis symptoms, coughing on most days, phlegm
production, wheezing and chest sounds without a cold. After adjustment for confounders, cannabis smoking
was not associated with an FEV1/FVC ratio o70% (P= 0.99).
Aldington
et al.20
339 Yes Both cannabis and tobacco-smoking groups showed a reduction in FEV1/FVC. Tobacco reduced FEV1, whereas
cannabis smoking had no effect on FEV1. Tobacco smoking was associated with macroscopic emphysema by
CT, but not cannabis-only smoking.
Tan et al.35 878 Yes Marijuana-only smokers had no signiﬁcant increase in risk for COPD as deﬁned by symptoms and spirometry.
However, concurrent use of tobacco and marijuana produced an increased risk for respiratory symptoms and
COPD.
Hancox
et al.32
1037 Yes After adjustment for tobacco, cannabis exposure was associated with increased FVC and TLC, but there was no
signiﬁcant association with FEV1 or FEV1/FVC. Cannabis was associated with increased Raw and lower sGaw.
Pletcher
et al.33
5119 Yes Marijuana exposure was non-linearly associated with lung function, unlike tobacco (Po0.001). Lifetime
marijuana exposure showed an increase in FEV1 over time at up to 7 joint-years and declining thereafter. FVC
was signiﬁcantly elevated even in heavy users up to 20 joint-years (Po0.001). Both FEV1 and FVC were
increased at all exposure levels compared with those in controls.
Kempker
et al.25
7716 Yes For cannabis smokers with 1–5 and 6–20 joint-years, there was no association with an FEV1/FVCo70%
(OR= 1.1). Those with over 20 joint-years did (OR= 2.1). Use of marijuana in the past month was associated with
increased FVC (0.13± 0.03%, P= 0.0001) for each additional day but no decrease in FEV1.
Macleod
et al.21
500 Yes Cannabis and tobacco use together was associated with increased cough, sputum production and wheeze.
After adjustment for tobacco use, age, gender and deprivation, each additional joint-year of cannabis was
associated with 0.3% increase in the prevalence of FEV1/FVCo70%.
Abbreviations: AHR, airway hyper-responsiveness; CT, computerised tomography; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity; sGaw, speciﬁc airway conductance; Raw, airway resistance; TLco, transfer factor of the lung for carbon monoxide.
aHancox et al.: a follow-up of two studies by Taylor et al.37,38; Sherrill et al.34: a follow-up of a study by Bloom et al.22
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Effects of tobacco smoking
The effects of cigarette (tobacco) smoking on lung health are well
known. They include symptoms of cough, sputum production
(which when marked constitutes chronic bronchitis), wheeze and
shortness of breath. Spirometric changes such as a progressive,
largely irreversible decrease in forced expiratory volume in 1 s
(FEV1) and FEV1 divided by forced vital capacity (FVC)− FEV1/FVC
ratio occur. This ratio is the most reliable measure of airﬂow
obstruction. These changes may be accompanied by air-trapping
within the lungs, measured physiologically (as increased total lung
capacity (TLC) or residual volume (RV) or the ratio RV/TLC) or
radiologically, on chest X-ray, etc. Chronic persistent, progressive
airway narrowing, damage to the alveoli (emphysema) and effects
on small airways (investigated with more sophisticated methods,
beyond the scope of this review), in varying proportions, comprise
the condition chronic obstructive pulmonary disease (COPD).
As cannabis was thought to affect the lungs in similar ways to
tobacco, it was logical to use spirometric measurements to detect
the adverse health effects of marijuana. However, with concurrent
tobacco smoking, it is difﬁcult to separate changes due to
cannabis from those due to tobacco.
The general paucity of data, the evolving nature of available
marijuana (newer, stronger forms, modes of inhalation, etc) and
the important confounding factor of tobacco use have led to
different interpretations of the health impact of marijuana by the
public as well as within the research and medical community.
The purpose of this review is to assess current knowledge of the
chronic effects of cannabis smoking on respiratory function and
the progression of pulmonary disease as well as to identify
potential directions for future research.
METHODS
MEDLINE/PubMed (NLM), Scopus (Elsevier) and Science Citation
Index Expanded (Web of Science) databases were searched for
English-language peer-reviewed articles from 1 January 1968 to
6 June 2015. These were reﬁned by the following search terms:
‘marijuana smoking lung’, ‘cannabis smoking lung’, ‘marijuana
smoking pulmonary’ and ‘cannabis smoking pulmonary’. This
method yielded 256 articles.
These initial 256 results were reduced to 114 peer-reviewed
articles, as the other 142 were not published in peer-reviewed
journals. The remaining 114 articles were individually screened by
title and abstract, looking for measurements of pulmonary
function and long-term cannabis use in humans. Case reports
and case series were omitted. The ﬁnal count contained 19 articles
ﬁtting all the above criteria. Each article was then individually
appraised, with the main ﬁndings and conclusions tabulated.
An additional search was also conducted for English-language
peer-reviewed articles, as above, containing the following search
terms: ‘cannabis bullous lung’, ‘cannabis bullae lung’, ‘cannabis
pneumothorax’ ‘bong lung’, ‘marijuana bullous lung’, ‘marijuana
bullae lung’ and ‘marijuana pneumothorax’. This yielded 69
articles, which were individually screened by title and abstract
for articles relating to bullous lung disease in marijuana smokers.
Case reports and case series were included in this search, and the
ﬁnal count contained 18 articles.
RESULTS
Simple lung function measurements
The results of these 19 studies are summarised in Table 1.
A total of 11 studies were cross-sectional,20,22–31 and 8 were
observational cohort studies.21,32–38 Eighteen out of 19 studies
included spirometric measurements in chronic marijuana
smokers.20–29,31–35,37–39 The results from these studies varied;
eight studies found no signiﬁcant changes in FEV1/FVC
ratio,23,24,26–29,32,35 whereas six studies found a signiﬁcant
decrease in FEV1/FVC in chronic marijuana-only smokers
compared with that in controls, with 0.5–1.9%
reduction.20–22,34,37,38 The remaining studies also varied in their
ﬁndings, but suggested that simply measuring the FEV1/FVC ratio
does not accurately reﬂect the pulmonary effects of chronic
marijuana use.
All studies reporting a signiﬁcant decrease, ~ 1.5%, in FEV1/FVC
ratio in marijuana smokers published incomplete data; in
particular, most omitted the absolute results for FVC alone.
However, two of these studies reported no signiﬁcant effect on
FEV1 in chronic cannabis use.
20,22 Sherrill et al.34 in a follow-up
survey of a random, stratiﬁed, cluster sample of the Tucson
population, aged 15–60 years (n= 856 who had at least two
measurements), found a reduction in FEV1/FVC of − 1.9 ± 0.7% and
in FEV1 of − 142 ± 44 ml only in previous marijuana smokers, with a
nonsigniﬁcant decrease of − 0.5 ± 0.6% in current marijuana
smokers.22 Surprisingly, in 1,239 of the same subjects, tested on
at least one occasion, FEV1/FVC was reduced by 0.5 ± 0.6% and
FEV1 increased by 58 ml. However, in a population-based cohort
born in 1972 and 1973 in Dunedin, New Zealand (n= 1,037),
Hancox et al. showed no signiﬁcant association between chronic
marijuana use and change in FEV1 or FEV1/FVC at age 32 but
found an increased FVC.32 Subsequently, both Pletcher et al., in a
longitudinal study over 20 years, recruited in 1985, examining
Coronary Artery Risk Development In 5115 young Adults, and
Kempker et al., in a cross-sectional study of 7,716 US adults from
the National Health And Nutrition Examination Study cohort
2007–2008 and 2009–2010 surveys, reported similar ﬁndings as
had Tilles et al. previously, although with a much smaller sample
size (n= 15 women).25,31,33 Pletcher et al., reported that FEV1
and FVC were 36 and 59 ml greater in cannabis users, with
410 joint-years’ smoking history, than in non-smoking controls.33
Kempker27 showed no effect on FEV1/FVC up to 20 joint-years but
over 20 joint-years was associated with a 2.1-fold risk for FEV1/FVC
ratio o70%, accounted for by a signiﬁcant increase in FVC and no
signiﬁcant reduction in FEV1.
25 Interestingly, Tashkin et al.29
reported a nonsigniﬁcant increase in both FEV1 and FVC in a
convenience sample of 144 heavy marijuana smokers compared
with other smoking groups, and in another study, in the same
subjects,39 found that heavy habitual marijuana use, over a period
of 8 years, was not associated with a decline in FEV1. Taken
together, this information suggests that, although in some cases
FEV1/FVC decreases by ~ 1.5% in chronic users, this may relate
more to an increase in FVC rather than to a reduction in FEV1. This
represents a major difference from the effects of tobacco smoking.
The possibility that the effect on FEV1 is due to selection of people
with higher FEV1 (because those with lower values do not smoke
or do not continue to smoke cannabis) cannot be excluded in
some of the studies.
Effects of dose and duration of exposure
Four studies found a dose-related response to marijuana
exposure.20,21,25,33 Using ANCOVA, Aldington et al. (n= 75 with a
mean of 54.2 joint-years) found that, for every joint-year of
smoking, there was a decrease in FEV1/FVC of 0.019%. Changes
due to chronic cannabis use (per joint-year) were also found in
speciﬁc airway conductance (−0.0017%), functional residual
capacity (+0.0013%) and TLC (+0.002%) but not in FEV1
(unfortunately FVC was not reported). From this, they estimated
that one pack-year of tobacco was equivalent to 4.1–7.9 joint-
years of cannabis smoking (alternatively 1 joint of cannabis was
equivalent to 2.5–5 cigarettes) in causing airﬂow obstruction.20
This was echoed by MacLeod et al., who found a 0.3% increase in
the prevalence of COPD (deﬁned by FEV1/FVCo0.70) for each
additional joint-year in marijuana and tobacco concurrent smokers
(n= 252) in their sample of 500 subjects recruited from a general
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practice in Edinburgh, Scotland. It is important to note that
subjects in this study were eligible for recruitment only if they
reported signiﬁcant tobacco or cannabis use, deﬁned as at least
5 pack-years and/or 1 joint-year, with none of their participants
smoking exclusively cannabis.21 Contrary to previous studies,
Pletcher et al. (n= 795 in Coronary Artery Risk Development In
5115 young Adults) noted that lifetime marijuana exposure was
associated with an increase in FEV1 up to 7 joint-years with a
decline thereafter at a slope of − 2.2 ml/joint-year, although FEV1
was still nonsigniﬁcantly higher than in controls at all exposure
levels (by 36 ml at410 joint-years lifetime exposure).33 FVC, even
after 20 joint-years, was still signiﬁcantly raised by 59 ml. In both
cases, however, FVC and FEV1 had a non-linear relationship with
marijuana, which again differs from that of tobacco smoking.33
Kempker et al. calculated in 855 cannabis smokers that, for each
additional joint-year smoked, there was no signiﬁcant change in
FEV1 %predicted (0.02+0.02), whereas FEV1/FVC decreased by
− 0.03 ± 0.01% (P= 0.02), accounted for by a signiﬁcant increase in
FVC 0.07+0.02% (P= 0.004).25
There is evidence that current use of marijuana may inﬂuence
spirometric measurements. Sherrill et al.34 reported that only
former cannabis smokers (n= 856) had decreased FEV1/FVC ratios,
with no signiﬁcant change in current smokers. In support,
Kempker et al. found that use of cannabis in the past month
was associated with an increased FVC for each additional day,
with no FEV1 decrease.
25 Eight of the 19 studies reported no
criteria for abstinence from marijuana before spirometric
testing.21,22,24,34,37–39 Strictly this confounds interpretation, making
it difﬁcult to distinguish acute from chronic effects of marijuana as
acute bronchodilator effects of d-9-THC can be seen 2–3 h after
inhalation6,40 and up to 6 h after oral ingestion.5
Other measures of lung function
Very few studies have examined more sophisticated measure-
ments of lung physiology. Aldington et al. found a very small
increase in plethysmographic TLC of 0.14 l in cannabis users in a
convenience sample from the Greater Wellington region, New
Zealand, which was supported by similar ﬁndings by Hancox et al.,
who reported an increase of just 0.03 l with an increase of 0.01 l in
functional residual capacity and RV.32 Tilles et al. also found that
marijuana smokers (n= 15) had a TLC of 108 ± 15% of predicted,
which was signiﬁcantly raised.31 Increased RV may indicate early
signs of small airway dysfunction and air-trapping; however, it is
not a very speciﬁc measure of small airway disease.41 Conversely,
results from Tashkin et al.28,29 (n= 74 and n= 144) showed no
signiﬁcant changes in multiple measures of small airway function
(FEV25–75%, closing volume, closing capacity, RV) between chronic
cannabis smokers and non-smoking controls.
Three studies also reported an association of chronic
cannabis smoking with increased airway resistance
(0.03–0.38 cm H2O/l/s)
28,29,32 and four studies found reduced
speciﬁc airway conductance (0.007–0.07 ml/s/cm H2O/l).
20,28,29,32
There was no association of these changes with change in lung
volume.32 Central airway secretions or inﬂammation or oedema
would be a potential explanation.
In studies measuring carbon monoxide transfer factor (TLco),
two small studies (n= 28 and n= 15) found a signiﬁcant decrease
in TLco with chronic concurrent marijuana and tobacco use down
to 65 ± 15% of predicted.27,31 However, these studies did not ﬁnd
a signiﬁcant reduction in TLco with marijuana-only use. Three
other larger studies also found no signiﬁcant decrease.20,29,32
Airway responsiveness was measured in three studies.24,30,38
Hernandez et al. studied 23 subjects from Texas, including six
marijuana smokers, using histamine to measure bronchial
responsiveness but found no difference in PD50 sRaw (dose of
histamine causing a 50% increase in speciﬁc resistance, sRaw) in
marijuana smokers compared with controls, whereas asthmatics
showed signiﬁcant hyper-reactivity to histamine. Larger studies by
Tashkin et al., in a convenience sample of 113 out of 542 subjects,
and by Taylor et al., in a sample of cannabis-dependent
21-year olds (n= 91), from 943 members of the Dunedin birth
cohort (n= 1037), measured metacholine responsiveness as the
provocative dose causing a 20% reduction in FEV1 (PC20). They
found no signiﬁcant difference in the number of marijuana-only
smokers who had a positive PC20 metacholine compared with that
in non-smokers. However, it is important to note that, after logistic
regression to control for the effect of tobacco and cocaine,
Tashkin et al. found that concurrent smokers of marijuana and
tobacco had a signiﬁcant association with hyper-responsiveness
to metacholine.
The relationship between tobacco and marijuana together on
lung function is complex and somewhat controversial. Sherman
et al. reported a reduction in FEV1/FVC and TLco in a marijuana
and tobacco-smoking group (n= 13) but no change in the
marijuana-alone group (n= 19).27 Tan et al. in a sample of 878
people over 40 years of age in Vancouver, Canada, also found a
signiﬁcant increase in respiratory symptoms in the marijuana and
tobacco-smoking group but not in the marijuana-only group.35
However, three other studies have reported no additive effects
on lung function of chronically smoking both marijuana and
tobacco.30,37,39
Respiratory symptoms
Eight out of nine studies, which quantiﬁed respiratory symptoms,
reported an increase in respiratory complaints with odds
ratios (ORs) of up to 2.98 compared with non-smoking
controls.20–22,26,28,29,34,38 Respiratory symptoms recorded included
increased incidence of cough, sputum production, shortness of
breath and wheeze. Taylor et al. also reported signiﬁcant increases
in exercise-related shortness of breath (OR 1.65), nocturnal
wakening with chest tightness (OR 1.72) and morning sputum
production (OR 2.44) in a birth cohort of 1,037 subjects at 21 years
of age.38 These ORs were even higher if casual cannabis users
were excluded. However, in a cross-sectional study of 6,728
subjects gathered from the National Health And Nutrition
Examination Study survey, which was conducted between 1988
and 1994, there was no association with shortness of breath (OR
1.29, P= 0.26) compared with non-smoking controls after adjust-
ing for age, although they did ﬁnd an increase in cough, phlegm,
wheezing and chronic bronchitis symptoms with similar OR to
tobacco users, which is interesting as in this sample marijuana
users were, on average, 10 years younger than tobacco smokers.26
Marijuana users (n= 414) were included in the sample if they had
smoked more than 100 cannabis cigarettes in total and had at
least 1 day of use in the previous month; they were not asked
about the frequency of use or overall exposure above 100
cigarettes. In addition to these nine studies, Hancox et al. also
found an association between cannabis and morning cough,
sputum production and wheeze compared with non-smokers.42
It was observed that cannabis smoke produces large airway
epithelial damage, oedema, erythema and increased secretions
with goblet cell hyperplasia,43 loss of ciliated epithelium and
squamous metaplasia on biopsy. There is also evidence of additive
bronchial epithelial damage in combined cannabis and tobacco
smokers.44
Effect of quitting cannabis smoking
Examining the effect of quitting is another approach to
determining the effect of smoking cannabis. The effect of quitting
cigarette (tobacco) smoking is well known.45–47 Unfortunately,
there are only two studies available of quitting cannabis.
Tashkin reported that in a convenience sample of 299 young
adults, including 95 regular cannabis-only smokers, 71 cannabis
and tobacco concurrent smokers and 49 tobacco-only smokers,
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those who became non-smokers of both substances had no
increased risk for chronic bronchitis compared with never smokers
at a mean of 9.8 years of follow-up.29,48 However, those who
continued smoking either substance had an increased risk for
chronic bronchitis over the follow-up period. Hancox et al.
analysed data from a well-characterised, population birth cohort
of 1,037 subjects followed from birth to age 38 years with
symptomatic assessment at 18, 26, 32 and 38 years of age.42
Frequent cannabis users numbered 157, 162, 138 and 99
compared with 540, 487, 608 and 703 non-users at different time
points. There were signiﬁcant reductions in morning cough,
sputum production and wheeze, but not shortness of breath on
exertion in the 26, 52, 54 and 50 quitters compared with
continuing smokers, whether of cannabis alone or cannabis and
tobacco. Furthermore, symptoms in the quitters were reduced to
levels similar to those in never users. Sherill et al. reported that the
risk for respiratory symptoms in previous non-tobacco smokers
reduced to normal after quitting, but a signiﬁcant reduction in
FEV1, FEV1/FVC and Vmax50 persisted in previous cannabis
smokers, although it was not present in current cannabis
smokers.34
Bullous lung disease and emphysema
Characteristic, peripheral, cystic changes on high-resolution
computed tomography scan are often found in patients who are
(probably heavy) cannabis smokers,49 although the speciﬁcity and
rate of occurrence of these ﬁndings are unclear. Only one
cross-sectional study, recruited from the Greater Wellington area,
measured radiological changes, reporting an increase in
rates of macroscopic emphysema in tobacco smokers (16% in
tobacco ± cannabis n= 183), but not in cannabis-only smokers
(1.3% of 75).20 However, the cannabis smokers showed a
signiﬁcant increase in low-density lung regions compared
with tobacco smokers, and this was interpreted as a result of
Table 2. Summary of case studies and case series on the association between cannabis smoking and bullous lung disease
Author (year) Subjects
(n)
Mean
age
Marijuana smoking Tobacco
smoking
(pack-years)
Results
Feldman
et al.71
1 24 14–28 g/week for
10 years
14 Spontaneous pneumothorax. Microscopy showed ruptured bulla, serosal
adhesions and focal atelectasis
Johnson
et al.49
4 38 2 joints/week to
3 joints/day
3–15 Bilateral upper zone peripheral bullae in all four cases. One with
paraseptal and two with apical bullous emphysema
Rawlins et al.72 2 29 Yesa Yesa Bilateral giant lung bullae and severe upper lobe emphysema
Thompson
et al.73
3 39 'Moderate' for 10 years
to 'heavy' for 24 years
9–20 Large upper lobe bullae
Phan et al.74 1 26 10 pipes a day for
5 years
1 Bilateral cystic and bullous changes in lower lobes. Microscopy showed
ﬁbrosis and macrophage inﬁltration
Beshay et al.75 17 27 53 joint-years 0–25 Multiple apical bullae or bullous emphysema in upper lobes. Histology
showed macrophages
Hii et al.51 10 41 11–149 joint-years 1–27 Asymmetrical bullae peripherally and centrally in upper and mid zones.
Reece76 1 56 10 cigarettes per day
for 25 years
41 Mixed tobacco and cannabis in joint. Multiple giant lung cysts on CT scan,
no lobe predominance.
Gao et al.77 1 23 Yesa None Cystic ﬁbrosis. Bilateral large upper lobe bullae. Recurrent pneumothorax
Allen78 1 18 1 oz weekly for 4 years 3 Bilateral apical bullae up to 3 cm. Histology showed emphysematous
changes with pigmented macrophages and
DIP-like changes.
Shah et al.79 1 27 ‘Heavy’ use for 10 years 20 Large left apical bulla and right apical blebs. CT scan following chest drain
of pneumothorax
Sood et al.80 1 33 ‘Off and on’ for 10 years 15 VLS on the left side shown on chest X-ray and CT scan
Gargani et al.81 2 41 Yesa NA to 39 One patient had left apical bullae, the other had right upper and middle
lobe bullae. In both patients, one bulla contained Aspergillus
Golwala82 1 25 24 joint-years 1 Bilateral bullae with upper lobe predominance. Previous untreated
sarcoidosis but no current clinical/radiological features
Tashtoush
et al.83
1 65 ‘Heavy ’ use for 20 years None Poorly controlled AIDS and previous IV heroin use. Bilateral large lung
bullae characteristic of VLS
Fiorelli et al.84 8 30 7 joints per week to
6 joints per day
15–40 Eight of 13 marijuana smokers with spontaneous pneumothorax had
bullae on CT scan. Six had paraseptal bullae and two had upper lobe
involvement
Cary et al.85 1 48 86 joint-years 25 Bilateral upper and mid zone bullous disease. Air ﬂuid level seen on left
lung bulla. Sputum grew only Candida; no clinical signs of infection.
Abbreviations: CT, computerised tomography; DIP, desquamative interstitial pneumonia; IV, intravenous; VLS, vanishing lung syndrome.
aUndocumented amount.
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airﬂow obstruction and hyperinﬂation rather than microscopic
emphysema.
Aside from the above-mentioned study, 7 case series and
10 case reports were also found, including a total of 56 marijuana
smokers presenting with bullous lung disease (often with
pneumothorax) with concurrent tobacco smoking present in all
but 3 cases. The results of these studies are summarised in Table 2.
One case report was excluded because of being included in a
subsequent case series.50,51 The majority of subjects in these cases
were heavy smokers of marijuana, although it is quite difﬁcult to
compare usage as the units of measurement varied. Seven case
series and six case reports had predominantly upper lobe
involvement (2 with Vanishing Lung Syndrome, VLS), and one
case report had predominantly lower lobe bullae. For those with
upper lobe involvement, the majority had peripheral emphysema.
Lung function was measured in four case series, with the majority
of cases having normal lung function results.
Cannabis and lung cancer
Currently, the evidence regarding an association of cannabis
smoking and lung cancer is inconclusive.52,53 Some studies have
found precancerous histological changes in bronchial biopsies of
marijuana smokers.44,54 However, epidemiological studies
have not found a deﬁnite association. A pooled analysis of
6 case–control studies with a total of 2,159 lung cancer cases and
2,958 controls found little or no association between cannabis
smoking and lung cancer; the overall pooled OR was 0.96
for habitual versus non-habitual smokers.55 Another large retro-
spective cohort study of 64,855 subjects found no increased risk
for cancer after 8.6 years, although their subjects were relatively
young even after follow-up.56 Other epidemiological studies have
reported associations with lung cancer with heavier marijuana use.
A 40-year longitudinal cohort study in 49,321 Swedish conscripts
found that those who smoked cannabis450 times had a twofold
risk of developing lung cancer.57 Although this study is large,
there are signiﬁcant ﬂaws in its methodology that limit the
conclusions that can be drawn. The subjects were only assessed
for tobacco and cannabis use at the time of conscription with no
information on use patterns before conscription and the 40 years
after conscription. A small case–control study in 403 subjects
(79 lung cancer patients including 14 heavy cannabis users) also
found, after adjusting for tobacco, an increased risk for lung
cancer for each joint-year smoked, although not in the 2 lowest
tertiles.58 However, owing to the small number of cases (n= 14)
and controls (n= 4), it is highly likely that relative risk estimates are
inﬂated.
DISCUSSION
Although there are clear inconsistencies between these 19 studies,
which may relate to subjects studied as well as methodology, we
can nevertheless draw various conclusions regarding the effects of
cannabis on lung function. Cannabis smokers usually also smoke
tobacco, either concomitantly or separately. This makes it difﬁcult
to disentangle the effects of the two. Quantiﬁcation of cannabis
use compounds the difﬁculty of dose–response studies. Although
studies consistently show the effects of cannabis on symptoms
(chronic bronchitis), there are mixed reports regarding airﬂow
obstruction. The larger cross-sectional and observational cohort
studies have found no association with reduced FEV1/FVC.
Self-selection (where subjects with a tendency to airway
narrowing reject cannabis smoking) cannot be excluded.
However, more recent, larger studies have found that chronic
cannabis users have an increased FVC alone, or in conjunction
with an increased FEV1.
32,33 A larger rise in FVC compared with
FEV1 could also contribute to previous observations of a decreased
FEV1/FVC ratio.
33
This contrasts with the reduced FEV1 and FEV1/FVC ratio
(indicating airﬂow obstruction) consistently associated with
cigarette smoking and COPD. The cause of the raised FVC in
chronic marijuana smokers is unclear. It has been suggested that it
might be because of training of respiratory muscles by the
characteristic inhalation techniques employed by marijuana
smokers.19,59,60 However, other evidence that training can increase
FVC by this amount in humans is scant.61 Bronchodilatation of
small airways can increase FVC, e.g., by up to 300 ml or 8.6% of
predicted after inhaled salbutamol 100 μg.62 An acute broncho-
dilator effect of cannabis is well described; in three studies,
marijuana was shown to increase FEV1 by 150–250 ml above
baseline.6 Relative preservation of FEV1 (36 ml greater in marijuana
smokers, with410 joint-years of exposure, compared with that in
controls) as found by Pletcher could relate to a bronchodilator
effect, as suggested by Kempker et al.25
The lack of a deﬁned marijuana abstinence period complicates
interpretation of spirometric results. Current cannabis smokers
had higher FVC values in studies of Kempker25 and Sherrill et al.34
Against this, tachyphylaxis to the bronchodilator effect would be
anticipated, and in studies in asthmatics acute bronchodilatation
lasted only about 2–6 h. The small but consistent increases in
airway resistance, and reduction in airway conductance,28,29,32
suggest small effects on central airways, which may be explained
by airway secretions, inﬂammation or oedema.
Another speculative, potential explanation for the absence
of chronic airﬂow obstruction with cannabis smoking may
relate to the well-documented anti-inﬂammatory and immuno-
modulatory effect of THC63—e.g., impairment of functional
activity of stimulated alveolar macrophages (antimicrobial and
respiratory burst, impaired cytokine production and nitric
oxide production)27,64–66 thought to be critical in COPD
pathogenesis.67–69
The clinical relevance of all this is unclear. COPD resulting from
an inﬂammatory response in the airways to tobacco smoking is a
major epidemic, currently the sixth leading cause of death
worldwide and projected to be the fourth leading cause of death
by 2030. Chronic marijuana smokers, who often also smoke
tobacco, present with similar chronic respiratory symptoms but do
not appear to develop airﬂow obstruction and COPD.
Future studies
In general, more information is required on cannabis smoking and
the lung. The difﬁculties with joint-years as the measure of
exposure have been mentioned. The observation that chronic
marijuana smokers generally buy and keep track of their supply in
grams suggests that grams per year may have advantages for
both clinicians and researchers. It has been reported that the
amount of cannabis purchased each month, and the intensity of
the high afterwards, predicted respiratory symptoms indepen-
dently of frequency of use.70 Although this will not overcome the
problems with self-reporting illegal substance use, it may serve as
a better measure of standardisation than joint-years.
Further research is necessary to clarify the relationship between
respiratory symptoms and lung function. Further studies are
needed to address acute bronchodilatation as a possible
confounding factor in studies on chronic airﬂow obstruction.
Serial examination of the bronchodilator effect of cannabis to look
for tachyphylaxis would be of interest. More research into the
effects of cannabis on the pathogenesis of COPD in relation to
small airway inﬂammation, cytokine production and macrophage
involvement is needed as well.
Other measures of airﬂow obstruction, including airway
resistance, plethysmographic lung volumes and particularly
measurements of small airways function, including imaging
studies, are required. The priority is to understand why tobacco
and cannabis smoking both cause chronic bronchitis yet have
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different effects on lung physiology. The pharmacological and
pathophysiological basis of this needs to be established.
More work is needed in quitters of cannabis smoking, including
motivations to quit, the effect on respiratory symptoms and lung
function and bronchoscopic biopsy studies, to examine the effects
on goblet cell hyperplasia and other histological ﬁndings.
CONCLUSIONS
This review clearly shows that chronic marijuana smoking is
associated with respiratory symptoms and increase in FVC. The
mechanisms for these effects and the differences from the effects
of tobacco remain unclear. More work needs to accurately
measure cannabis use as well as measure all aspects of respiratory
health, particularly breathlessness and exercise tolerance. More
importantly, however, there needs to be larger, longer-term
studies with marijuana smokers who do not smoke tobacco.
There is clear evidence that marijuana causes similar symptoms
to tobacco smoking (chronic bronchitis) and produces similar
large airway pathological features. There is some evidence that
the combination of tobacco and marijuana is additive. Tobacco
unequivocally causes chronic airﬂow obstruction and COPD but
only in a minority of smokers. Cannabis smoking, however,
produces an increase in FVC and the reason(s) for this are unclear
and require elucidation. Taking a more detailed history with
regard to cannabis smoking and other illicit inhalational drugs
should be part of the standard respiratory assessment of all
patients, which would also support better epidemiological data
collection for future studies, particularly in the primary care
population.
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